CR20110279A - PIRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS 10 - Google Patents

PIRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS 10

Info

Publication number
CR20110279A
CR20110279A CR20110279A CR20110279A CR20110279A CR 20110279 A CR20110279 A CR 20110279A CR 20110279 A CR20110279 A CR 20110279A CR 20110279 A CR20110279 A CR 20110279A CR 20110279 A CR20110279 A CR 20110279A
Authority
CR
Costa Rica
Prior art keywords
piridine
pyrimidine derivatives
phosphodiesterase inhibitors
pyrimidine
compounds
Prior art date
Application number
CR20110279A
Other languages
Spanish (es)
Inventor
Jennifer R Allen
Kaustav Biswas
Frank Chavez
Ning Chen
Frenel Fils Demorin
James R Falsey
Mike Frohn
Paul Harrington
Daniel B Horne
Essa Hu
Matthew R Kaller
Roxanne Kunz
Holger Monenschein
Tom Nguyen
Alex Pickrell
Andreas Reichelt
Shannon Rumfelt
Rob Rzasa
Kelvin Sham
Guomin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20110279A publication Critical patent/CR20110279A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de piridina y pirimidina y composiciones que los contienen, y proceso para preparar tales compuestos.The present invention relates to pyridine and pyrimidine compounds and compositions containing them, and process for preparing such compounds.

CR20110279A 2008-11-14 2011-05-26 PIRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS 10 CR20110279A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11459508P 2008-11-14 2008-11-14
US16621509P 2009-04-02 2009-04-02

Publications (1)

Publication Number Publication Date
CR20110279A true CR20110279A (en) 2011-09-22

Family

ID=41557471

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110279A CR20110279A (en) 2008-11-14 2011-05-26 PIRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS 10

Country Status (17)

Country Link
US (2) US8318718B2 (en)
EP (1) EP2364306B1 (en)
JP (1) JP2012508777A (en)
KR (1) KR20110086603A (en)
AR (1) AR074343A1 (en)
AU (1) AU2009313773B2 (en)
BR (1) BRPI0921598A2 (en)
CA (1) CA2742833C (en)
CR (1) CR20110279A (en)
EA (1) EA201100749A1 (en)
ES (1) ES2413808T3 (en)
IL (1) IL212670A0 (en)
MA (1) MA32891B1 (en)
MX (1) MX2011005093A (en)
TN (1) TN2011000220A1 (en)
TW (1) TW201030001A (en)
WO (1) WO2010057126A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102223797A (en) 2008-11-21 2011-10-19 高点制药有限责任公司 Adamantyl benzamide compounds
ME02337B (en) 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Pyridazinone compounds
MY165585A (en) 2010-06-24 2018-04-05 Takeda Pharmaceuticals Co Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
JP5760085B2 (en) * 2010-08-04 2015-08-05 武田薬品工業株式会社 Fused heterocyclic compounds
WO2012018058A1 (en) 2010-08-04 2012-02-09 武田薬品工業株式会社 Fused heterocyclic ring compound
EP2604597B1 (en) 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
CN103619841B (en) 2011-01-11 2017-03-29 桑诺维恩药品公司 Heteroaryl compound and its using method
JP2014510055A (en) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as phosphodiesterase 10 (PDE10A) inhibitors
WO2012124782A1 (en) 2011-03-16 2012-09-20 武田薬品工業株式会社 Condensed heterocyclic compound
DK2718270T3 (en) * 2011-06-10 2022-08-01 Merck Patent Gmbh COMPOSITIONS AND METHODS FOR THE PREPARATION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK-INHIBITING ACTIVITY
TWI570122B (en) 2011-06-22 2017-02-11 武田藥品工業股份有限公司 Crystal of fused heterocyclic compound
EA201490152A1 (en) 2011-06-24 2014-05-30 Эмджен Инк. TRPM8 ANTAGONISTS AND THEIR APPLICATION IN TREATMENT
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
BR112014004310B8 (en) * 2011-08-25 2023-04-18 Merck Sharp & Dohme PHOSPHODIESTERASE 10 ENZYME INHIBITOR PYRMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JPWO2014142322A1 (en) 2013-03-15 2017-02-16 第一三共株式会社 Benzothiophene derivatives
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
RU2016110852A (en) 2013-09-27 2017-10-30 Нимбус Айрис, Инк. IRAK INHIBITORS AND THEIR APPLICATIONS
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
RU2732416C2 (en) * 2014-07-31 2020-09-16 Институт Пастер Корея 2-amino-benzimidazole derivatives and use thereof as 5-lipoxygenase and/or prostaglandin e-synthase inhibitors
CA2997537C (en) 2015-09-18 2024-02-13 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
CN110563664A (en) * 2019-07-23 2019-12-13 上海合全药物研发有限公司 Method for preparing racemic (4AS,7S,7AS) -tert-butyl-7-hydroxy hexahydro-cyclopenta [ B ] [1,4] oxazine-4 (4AH) -formic acid ester
WO2022238327A1 (en) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
PT1635828E (en) 2003-04-04 2008-07-01 Lundbeck & Co As H 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
DE10337942A1 (en) 2003-08-18 2005-03-17 Merck Patent Gmbh aminobenzimidazole derivatives
DE10344223A1 (en) 2003-09-24 2005-04-21 Merck Patent Gmbh New 2-anilino-1,3-benzoxazole derivatives, are inhibitors of kinases, especially tyrosine- or Raf-kinases, useful e.g. for treating solid tumors, angiogenesis, diabetic retinopathy, inflammation or psoriasis
DE10349587A1 (en) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
DE102005016634A1 (en) 2005-04-12 2006-10-19 Merck Patent Gmbh Novel aza heterocycles as kinase inhibitors
EP1912959A2 (en) 2005-08-02 2008-04-23 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
NL2000397C2 (en) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclic heteroaryl compounds as PDE10 inhibitors.
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof

Also Published As

Publication number Publication date
MA32891B1 (en) 2011-12-01
US8318718B2 (en) 2012-11-27
US20130079325A1 (en) 2013-03-28
CA2742833A1 (en) 2010-05-20
US8759532B2 (en) 2014-06-24
EP2364306B1 (en) 2013-04-24
EA201100749A1 (en) 2011-10-31
EP2364306A1 (en) 2011-09-14
TN2011000220A1 (en) 2012-12-17
KR20110086603A (en) 2011-07-28
WO2010057126A1 (en) 2010-05-20
AU2009313773B2 (en) 2013-03-21
TW201030001A (en) 2010-08-16
CA2742833C (en) 2013-12-31
AU2009313773A1 (en) 2010-05-20
ES2413808T3 (en) 2013-07-17
IL212670A0 (en) 2011-07-31
JP2012508777A (en) 2012-04-12
MX2011005093A (en) 2011-09-27
US20100125062A1 (en) 2010-05-20
BRPI0921598A2 (en) 2016-02-10
AR074343A1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
CR20110279A (en) PIRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS 10
DOP2011000175A (en) ORGANIC COMPOUNDS
PH12014502169A1 (en) N-cyclylamides as nematicides
DOP2011000176A (en) ORGANIC COMPOUNDS
GB201106829D0 (en) Heterocyclic compounds
CR20110028A (en) PIRIMIDINE DERIVATIVES AS CINASE INHIBITORS
BR112012032244A2 (en) process for preparing tetrazole-substituted anthranilamide derivatives and new crystalline polymorphs and derivatives thereof
CO6831982A2 (en) Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors
CR20110467A (en) DERIVATIVES OF BENZOFURANILO AS INHIBITORS OF GLUCOQUINASE
BR112012010186A2 (en) heteroaryl derivatives containing n as jak3 kinase inhibitors.
CO6321282A2 (en) PIPERIDINYLINDOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
BRPI0911208A2 (en) antioxidant inflammatory modulators: oleanolic acid derivatives with c-ring saturation.
CR11427A (en) 2-FLUORO-2 - DEOXITETRAHYDROURIDINS AS INHIBITORS OF CITIDINE DESAMINASE
UY32611A (en) 1-CYANOETHYLETHYCLIC CARBOXAMIDE SUBSTITUTED COMPOUNDS 750
MX2009007302A (en) Purine derivatives.
CR20110286A (en) PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES
BR112012029647A2 (en) new pyrimidine derivatives
WO2008124129A3 (en) Treating hiv with a m-csf effector kinase inhibitor like imatinib
TN2015000261A1 (en) Imidazopyridazine derivatives as gabaa receptor modulators
EA201270280A1 (en) Pyrimidine Compounds as Inhibitors in the Treatment of Tuberculosis
DOP2015000059A (en) AMINO-QUINOLINAS AS KINASE INHIBITORS
SV2009003429A (en) DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
UY29667A1 (en) NEW PIRIDINE COMPOUNDS, PHARMACCUTIC COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
CU20180028A7 (en) IMIDAZO DERIVATIVES [4,5-b] PIRIDINE, USEFUL AS DYRK1 / CLK1 DUAL INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MX2015013365A (en) Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)